Introduction: Since the presence of three or more NNRTI mutations V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V and G190A/S results in no response to etravirine treatment, the presence of two of these NNRTI mutations and N348I at baseline may also reduce etravirine efficacy in vivo.
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
PMID: 20102271
2010
The Journal of infectious diseases
Result: No resistance mutations were detected in 27 (41.5%), K103N was detected in 25 (38.5%), Y181C in 5 (7.7%) and K101E in 4 (6.2%); 2 of these 4 [3.1%] also had the K103N mutation (Table 2).
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
PMID: 20102272
2010
The Journal of infectious diseases
Method: For single-genome sequencing analyses, a total of 27 subjects (15 NNRTI-naive
Result: NNRTI-experienced subject 5E had two distinct populations of sequences at entry, one wildtype and one containing several linked NNRTI-resistance mutations (K101E/Y181C/G190A).
Result: For NNRTI-experienced subject 3E, entry sequences containing K101E showed a trend toward clustering (bootstrap value 46) with failure sequences containing L100I/K101E/Y188L or L100I/K101E/G190A (figure 2E).
Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed hiv type 1-infected patients in Shandong Province, China.
PMID: 20121622
2010
AIDS research and human retroviruses
Abstract: Forty-six of the 47 successfully genotyped DBS had no transmitted DR mutations; one had an NNRTI mutation (K101E) in the RT region.
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Result: Five PHPT-4 subjects and eight PHPT-2 controls had minor NNRTI mutations in postpartum samples (V179D, K101E, V106I, or V90I).
Table: K101E
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
Abstract: The most common etravirine resistance associated mutations were Y181C (42.9%), G190A (25.3%), H221Y (19.8%), A98G (18.7%), K101E (16.5%), and V90I (12.1%).
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
Abstract: Frequent RAMs were Y181C, G190A, K101E and A98G, whereas V179F, Y181V and G190S appeared in <5% of sequences.
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
Abstract: K101E+G190S reduced fitness in the absence of EFV and increased EFV resistance, compared to either single mutant.
Abstract: Addition of the nucleoside resistance mutations L74V or M41L+T215Y to K101E+G190S improved fitness and abolished EFV-dependent stimulation of replication.
Abstract: D10, a clinical RT backbone containing M41L+T215Y and K101E+G190S, also demonstrated EFV-dependent stimulation that was dependent on the presence of K101E.
Abstract: Unexpectedly, K101E+
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Result: Figure 1a shows the 16 mutations that occurred significantly more commonly in efavirenz-exposed individuals (L100I, K101P, K103N, V106I/M, V108I, V179D, Y188H/L, G190E/S/Q, P225H, F227Y, M230L and K238T), and Figure 1b shows the 12 that occurred significantly more commonly in nevirapine-exposed individuals (A98G, K101E, K103S, V106A, E138A, T139
HIV mutation literature information.
PMID: 
2010
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT